Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (162)	6/21/2001 7:57:03 PM
From: Biomaven	Respond to of 1005

tuck, <<POZN>> This isn't really a pharmacogenomic issue - it's just that there are various grades of migraine and they are trying to cover the spectrum from the relatively mild (the NSAID combo) through the triptan combo to the most intractable(DHE combo). The stock (like most of the BLUE denizens) has been pretty weak. At some point this will turn - from a pure valuation perspective the BLUE's look the most attractive sector right now. Alas this doesn't mean they won't continue weak for a while yet, but at some point the sellers will hopefully be done. Peter